文献速递食管与纵隔外科

改良剑突下胸腔镜胸腺切除术治疗T2-3期胸腺恶性肿瘤的围手术期结局与生存:一项回顾性对比研究

Perioperative outcomes and survival of modified subxiphoid video-assisted thoracoscopic surgery thymectomy for T2-3 thymic malignancies: A retrospective comparison study.
PubMed 文献 · J Thorac Cardiovasc Surg · 2024-04-30

本研究基于前瞻性维护数据库,纳入2015至2020年221例T2-3期胸腺恶性肿瘤患者,经1:1倾向性评分匹配后每组72例,比较改良剑突下胸腔镜胸腺切除术与正中胸骨切开术的围手术期及肿瘤学结局。结果显示改良剑突下组手术时间更短、出血更少、引流时间及住院时间更短、术后并发症更少,完全切除率及生存无显著差异。作者认为该术式安全有效,可作为部分局部晚期胸腺疾病患者的替代选择,但需进一步前瞻性研究评估长期生存。

要点

  • 倾向性评分匹配后每组72例,改良剑突下组手术时间98 vs 129分钟,出血40 vs 100 mL,P均<.001。
  • 改良剑突下组术后并发症5.6% vs 23.6%(P=.005),完全切除率98.6% vs 98.6%(P=1.000)。
  • 两组无复发生存(HR 0.94,95%CI 0.40-2.20,P=.883)与总生存(HR 0.52,95%CI 0.05-5.02,P=.590)相似。

核心结论

  • 改良剑突下胸腔镜胸腺切除术对T2-3期胸腺恶性肿瘤安全有效,可作为部分局部晚期胸腺疾病患者的替代选择。
  • 作者指出需进一步前瞻性研究评估接受改良剑突下入路胸腔镜胸腺切除术患者的长期生存。

研究设计与样本

  • 回顾性对比研究,纳入2015至2020年221例T2-3期胸腺恶性肿瘤患者,均来自前瞻性维护数据库。
  • 采用1:1倾向性评分匹配平衡偏倚,最终每组72例;采用改良切除指数评估手术难度。

主要发现

  • 改良剑突下组手术时间98 vs 129分钟(P<.001),出血量40 vs 100 mL(P<.001),引流时间3 vs 5天(P<.001),住院时间5 vs 6天(P<.001)。
  • 改良剑突下组术后并发症5.6% vs 23.6%(P=.005),完全切除率98.6% vs 98.6%(P=1.000)。
  • 106例中5例(4.7%)发生中转。
  • 无复发生存HR 0.94(95%CI 0.40-2.20,P=.883),总生存HR 0.52(95%CI 0.05-5.02,P=.590),两组相似。

临床怎么用

  • 作者认为改良剑突下胸腔镜胸腺切除术对T2-3期胸腺恶性肿瘤安全有效,可作为部分局部晚期胸腺疾病患者的替代选择。
  • 作者指出需进一步前瞻性研究评估该术式患者的长期生存。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Our previous study demonstrated that modified subxiphoid video-assisted thoracic surgery thymectomy with an auxiliary sternal retractor is feasible for locally invasive thymic malignancies. This study aimed to compare perioperative and oncological outcomes of modified subxiphoid video-assisted thoracoscopic surgery thymectomy versus median sternotomy thymectomy for locally advanced thymic malignancies. METHODS: In total, 221 patients with T2-3 thymic malignancies who underwent modified subxiphoid video-assisted thoracoscopic surgery thymectomy or median sternotomy thymectomy between 2015 and 2020 were enrolled in our prospectively maintained database. A 1:1 propensity score-matching analysis was performed to balance the bias. Surgical difficulty was evaluated with a modified resection index. Perioperative and oncological results were compared between the modified subxiphoid video-assisted thoracoscopic surgery thymectomy group and the median sternotomy thymectomy group. RESULTS: There were 72 patients in each group in the final analysis. Our results showed that the modified subxiphoid video-assisted thoracoscopic surgery thymectomy group had a shorter operative duration (98 vs 129 minutes, P < .001), less blood loss (40 vs 100 mL, P < .001), shorter drainage duration (3 vs 5 days, P < .001), shorter length of hospital stay (5 vs 6 days, P < .001), and fewer postoperative complications (5.6% vs 23.6%; P = .005). No significant difference was detected in complete resection (98.6% vs 98.6%, P = 1.000) between the 2 groups. Conversion occurred in 5 of 106 patients (4.7%). Survival analyses indicated similar recurrence-free survival (hazard ratio, 0.94; 95% CI, 0.40-2.20; P = .883) and overall survival (hazard ratio, 0.52; 95% CI, 0.05-5.02; P = .590) between the 2 groups. CONCLUSIONS: Modified subxiphoid video-assisted thoracoscopic surgery thymectomy was safe and effective for T2-3 thymic malignancies and could be an alternative for selected patients with locally advanced thymic diseases. Further prospective studies are needed to evaluate the long-term survival of those undergoing modified subxiphoid approach thoracoscopic thymectomy.

来源:J Thorac Cardiovasc Surg,查看原文。版权归原作者所有。

引用

  1. Yang X, Jiang J, Ao Y, et al. Perioperative outcomes and survival of modified subxiphoid video-assisted thoracoscopic surgery thymectomy for T2-3 thymic malignancies: A retrospective comparison study. J Thorac Cardiovasc Surg. 2024. PMID: 38692477. doi:10.1016/j.jtcvs.2024.04.023

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。